Table 3 The association of TMB levels and genomic alterations.
From: Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
| Â | mutation status | TMB, median (range), mutations/Mb | P valuea | TMB level | P valueb | |
|---|---|---|---|---|---|---|
Low (%) | Moderate to high (%) | |||||
BRCA1 | mutated | 5.68 (0–22.26) | 0.015 | 3 (42.86%) | 4 (57.14%) | 0.005 |
|  | wild type | 0.36 (0–41.45) |  | 93 (84.55%) | 17 (15.45%) |  |
FBXW7 | mutated | 4.80 (0.45–22.26) | 0.003 | 2 (40%) | 3 (60%) | 0.012 |
|  | wild type | 0.36 (0–41.45) |  | 94 (83.93%) | 18 (16.07%) |  |
PIK3R1 | mutated | 13.77 (2.30–13.79) | 4.46E-05 | 1 (33.33%) | 2 (66.67%) | 0.026 |
|  | wild type | 0.36 (0–41.45) |  | 95 (83.33%) | 19 (16.67%) |  |
POLE | mutated | 23.73 (6.66–40.81) | 0.005 | 0 (0%) | 2 (100%) | 0.002 |
|  | wild type | 0.36 (0–41.45) |  | 96 (83.48%) | 19 (16.52%) |  |
PTEN | mutated | 2.64 (0–41.45) | 0.000995 | 10 (55.56%) | 8 (44.44%) | 0.001 |
|  | wild type | 0.35 (0–40.81) |  | 86 (86.87%) | 13 (13.13%) |  |
STK11 | mutated | 20.41 (0–40.81) | 0.028 | 1 (50%) | 1 (50%) | 0.234 |
|  | wild type | 0.37 (0–41.45) |  | 95 (82.61%) | 20 (17.39%) |  |
TSC2 | mutated | 40.81 (13.78–41.45) | 3.83E-11 | 0 (0%) | 3 (100%) | 0.005 |
|  | wild type | 0.36 (0–22.26) |  | 96 (84.21%) | 18 (15.79%) |  |
AKT1 | mutated | 1.15 (0–2.30) | 0.802 | 2 (100%) | 0 (0%) | 0.505 |
|  | wild type | 0.37 (0–41.45) |  | 94 (81.74%) | 21 (18.26%) |  |
ARID1A | mutated | 1.15 (0–9.77) | 0.135 | 7 (70%) | 3 (30%) | 0.299 |
|  | wild type | 0.37 (0–41.45) |  | 89 (83.18%) | 18 (16.82%) |  |
ATR | mutated | 2.84 (0–5.68) | 0.245 | 1 (50%) | 1 (50%) | 0.234 |
|  | wild type | 0.37 (0–41.45) |  | 95 (82.61%) | 20 (17.39%) |  |
BRAF | mutated | 2.98 (0.69–4.80) | 0.488 | 2 (66.67%) | 1 (33.33%) | 0.482 |
|  | wild type | 0.37 (0–41.45) |  | 94 (82.46%) | 20 (17.54%) |  |
BRCA2 | mutated | 4.25 (0–22.26) | 0.166 | 2 (50%) | 2 (50%) | 0.089 |
|  | wild type | 0.36 (0–41.45) |  | 94 (83.19%) | 19 (16.81%) |  |
CTNNB1 | mutated | 0 (0–22.26) | 0.313 | 4 (80%) | 1 (20%) | 0.903 |
|  | wild type | 0.38 (0–41.45) |  | 92 (82.14%) | 20 (17.86%) |  |
FAT1 | mutated | 2.40 (0–4.80) | 0.245 | 1 (50%) | 1 (50%) | 0.234 |
|  | wild type | 0.37 (0–41.45) |  | 95 (82.61%) | 20 (17.39%) |  |
FGFR2 | mutated | 2.30 (0–6.66) | 0.488 | 2 (66.67%) | 1 (33.33%) | 0.482 |
|  | wild type | 0.37 (0–41.45) |  | 94 (82.46%) | 20 (17.54%) |  |
HRAS | mutated | 3.2 | 0.896 | 1 (100%) | 0 (0%) | 0.639 |
|  | wild type | 0.37 (0–41.45) |  | 95 (81.90%) | 21 (18.10%) |  |
KRAS | mutated | 0.22 (0–4.53) | 0.782 | 5 (83.33%) | 1 (16.67%) | 0.933 |
|  | wild type | 0.37 (0–41.45) |  | 91 (81.98%) | 20 (18.02%) |  |
NF1 | mutated | 0.37 | 0.896 | 1 (100%) | 0 (0%) | 0.639 |
|  | wild type | 0.37 (0–41.45) |  | 95 (81.90%) | 21 (18.10%) |  |
PIK3CA | mutated | 1.34 (0–40.81) | 0.114 | 12 (66.67%) | 6 (33.33%) | 0.061 |
|  | wild type | 0.36 (0–41.45) |  | 84 (84.85%) | 15 (15.15%) |  |
TP53 | mutated | 0.76 (0–22.26) | 0.265 | 41 (89.13%) | 5 (10.87%) | 0.108 |
|  | wild type | 0 (0–41.45) |  | 55 (77.46%) | 16 (22.54%) |  |
